Navigation Links
QuantaLife, Inc. Closes $17.2M Series B Financing to Accelerate Application Development for Its Droplet Digital™ PCR Platform and Establish Commercial Operations by 2011
Date:12/10/2010

PLEASANTON, Calif., Dec. 10, 2010 /PRNewswire/ --

QuantaLife, Inc. announced today that it has closed a $17.2M Series B financing. The majority of the proceeds will be used to establish commercial operations for introduction of its first product, the Droplet Digital™ PCR platform, into the life sciences research market early next year and accelerate development of targeted diagnostic tests. Paladin Capital Group, together with other existing investors reiterated their strong support and was joined by Merieux Developpement and Vital Financial LLC, as new investors. According to Dr. Bill Colston, Founder and Chief Executive Officer of QuantaLife, "Droplet Digital PCR establishes a new standard for nucleic acid measurement, including the absolute quantification of DNA, RNA, and miRNA. It has a myriad of potential uses – in the research laboratory and in the clinic. With the completion of this financing, we have diversified our world-class investor base and are well positioned for a successful transition to commercialization.   We look forward to bringing a cost-effective and reliable product to the research community."

"QuantaLife's technology is very compelling and represents a unique opportunity to establish a new standard for the future of genomics research and nucleic acid testing, with a simple, reliable and cost-effective solution. We look forward to working with QuantaLife's management team and existing shareholders to help establish the company as a global leader in the emerging digital PCR market," said Francois Valencony, Managing Director of Merieux Developpement.

About QuantaLife, Inc.

QuantaLife has developed 3rd generation PCR technology that quantifies DNA molecules by Droplet Digital PCR. Droplet Digital PCR measures target nucleic acid target molecules with unrivaled absolute quantitative resolution and sensitivity. Applications include copy number variation (CNV), mutation detection, and gene expression analysis. The company's mission is to provide tools that accelerate new strategies for the diagnosis and treatment of inherited disorders, cancer, and infectious disease.

About Paladin Capital Group

Paladin Capital Group is an established, multi-stage private equity firm that invests in growing companies through acquisitions and expansion capital. Headquartered in Washington D.C., with offices in New York City and Atlanta, GA, Paladin has more than $950 million of committed capital across several distinct funds.

About Merieux Developpement

Merieux Developpement is the healthcare investment company of Institut Merieux, a French industrial holding company dedicated to biology, which currently employs more than 10,000 people worldwide. Institut Merieux has majority ownership of bioMerieux (NYSE Euronext, BIM), Silliker, Transgene (NYSE Euronext, TNG) and ABL Inc. Merieux Developpement intends to invest up to euro 70 million as minority shareholder from 2010 to 2013 in the field of healthcare on a global basis, working alongside entrepreneurs and innovative companies whose products and services can bring genuine advances to the health of patients and consumers worldwide. More information can be found at www.merieux-developpement.com


'/>"/>
SOURCE QuantaLife, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. QuantaLife, Inc. Unanimously Selected as the Most Promising Company at the Personalized Medicine World Conference 2010
2. OncoGenex Pharmaceuticals, Inc. Closes $50 Million Public Offering
3. NEURO-BIOTECH DISCLOSES ITS LIST OF LICENSES
4. Cylene Initiates Phase I Trial in Multiple Myeloma With CX-4945 Inhibitor of CK2 and Closes Accompanying Financing
5. Calithera Biosciences Closes $40 Million in Series A Financing
6. Pharmalink AB Closes Deal With Grifols SA for the Acquisition of the Xepol(R) Programme for the Treatment of Post-Polio Syndrome
7. ERT Closes the Acquisition of the Research Services Division of CareFusion Corporation
8. YM BioSciences closes US$17.5 million financing
9. BioMS Medical reports Spectral receives FDA approval to initiate pivotal trial and closes financing for $19.5 million
10. Viroblock SA Hires Dr. Jamie Paterson as CEO and Closes Financing Round
11. The MedZilla Report for January 2010 - Health Care Closes 2009 Strong, But Pharma Continues Shedding Jobs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... Ginkgo Bioworks , a leading organism design company ... as one of the World Economic Forum,s Technology ... companies. Ginkgo Bioworks is engineering biology to manufacture ... the nutrition, health and consumer goods sectors. The ... Fortune 500 companies to design microbes for their ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/24/2016)... Raleigh, NC (PRWEB) , ... June 24, 2016 , ... ... find the most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings ... here to read it now. , Diagnostic biomarkers are signposts in the blood, ...
(Date:6/23/2016)... ... June 23, 2016 , ... UAS ... the launch of their brand, UP4™ Probiotics, into Target stores nationwide. The company, ... proud to add Target to its list of well-respected retailers. This list includes ...
Breaking Biology Technology:
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
(Date:4/13/2016)... CHICAGO , April 13, 2016  IMPOWER physicians ... are setting a new clinical standard in telehealth ... By leveraging the higi platform, IMPOWER patients can ... weight, pulse and body mass index, and, when they ... quick and convenient visit to a local retail location ...
(Date:3/31/2016)... PROVIDENCE, R.I. , March 31, 2016  Genomics ... leadership of founding CEO, Barrett Bready , M.D., ... addition, members of the original technical leadership team, including ... Vice President of Product Development, Steve Nurnberg and Vice ... have returned to the company. Dr. Bready ...
Breaking Biology News(10 mins):